RxDoctor Payments Data

Syed Rizvi, MD

Psychiatry · Manassas, VANPI 1396824363

Payments from drug & device makers

$6,917in general payments, 2019–2025

Across 391 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$751
  • Alkermes, Inc.$717
  • Vanda Pharmaceuticals Inc.$493
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$464
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,77898%
  • Education$1392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,917 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$20,595
Medicare patients
58
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$61,611
VraylarCariprazine Hcl13$18,742
SaphrisAsenapine Maleate13$15,698
Divalproex Sodium ErDivalproex Sodium166$13,106
Quetiapine Fumarate178$6,663
Aripiprazole69$5,061
BelsomraSuvorexant11$4,920
Atomoxetine Hcl34$4,544
Ziprasidone Hcl34$4,118
Clozapine47$4,032
Olanzapine105$3,952
QelbreeViloxazine Hcl11$3,215
Lurasidone Hcl15$3,178
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$2,379
Risperidone120$2,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,054$61,61119 claims
AbbVieVraylar, Saphris$1,076$34,44026 claims
Supernus Pharmaceuticals, Inc.Qelbree$400$3,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →